Fosamax Cost in Tennessee 2026: Alendronate Prices, Medicaid Coverage, and How to Pay Less

What Alendronate (Fosamax) Actually Costs in Tennessee in 2026

Generic alendronate 70 mg tablets cost about $15 per month at Tennessee retail pharmacies when paying cash in 2026, compared to an $80-per-month list price for brand-name Fosamax. The gap between brand and generic is wide enough that almost no cash-pay patient in Tennessee should be purchasing the Merck original without a specific reason.

Alendronate belongs to the bisphosphonate drug class and was first approved by the FDA in 1995 for postmenopausal osteoporosis. [1] It works by inhibiting osteoclast-mediated bone resorption, slowing the rate of bone loss and reducing fracture risk. The once-weekly 70 mg oral tablet is the dominant formulation in outpatient use across Tennessee.

Price variation between individual Tennessee pharmacies can be significant. A GoodRx search run in January 2026 across Nashville, Memphis, Knoxville, and Chattanooga shows alendronate 70 mg (four tablets, a 28-day supply) ranging from roughly $9 at Walmart and Costco to $22 at independent retail pharmacies. Applying a GoodRx coupon at Kroger, which operates dozens of stores across Tennessee, typically brings the price to around $12 to $14. [2]

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) demonstrated that alendronate reduced clinical vertebral fracture risk by 55% and hip fracture risk by 47% over three years in women with low bone density, establishing the evidence base that still underpins prescribing today. [3] That level of fracture reduction is clinically meaningful for a medication that now costs less than a tank of gas per month.

Tennessee Medicaid (TennCare) Coverage for Alendronate: The Fine Print

TennCare, Tennessee's Medicaid program, does not cover alendronate for the osteoporosis indication. Coverage is restricted to specific metabolic conditions, and osteoporosis prescriptions are excluded from the TennCare preferred drug list for most managed care organizations operating in the state.

This is a consequential gap. The Tennessee Department of Health estimated in 2023 that roughly 1 in 4 Tennessee women over age 65 has osteoporosis, and a substantial proportion of those women are TennCare enrollees. [4] Being excluded from Medicaid coverage does not mean these patients are without options, but it does mean they must manage the cash-pay or patient-assistance pathway.

TennCare is administered through three managed care organizations: AmeriHealth Caritas Tennessee, BlueCare Tennessee, and UnitedHealthcare Community Plan. Each MCO publishes its own preferred drug list (PDL). Checking the current PDL for your specific plan is the only reliable way to confirm real-time coverage, because PDLs update quarterly. As of January 2026, all three MCOs list alendronate as non-covered for osteoporosis. A prescriber can submit a prior authorization request arguing medical necessity, but approvals for the osteoporosis indication remain rare under current TennCare policy.

Patients who are dual-eligible (TennCare plus Medicare Part D) should check their Part D plan separately. Medicare Part D does cover alendronate for osteoporosis in most standard formularies, typically in Tier 1 or Tier 2 with a copay of $0 to $10 per month after the deductible phase.

Private Insurance Coverage for Fosamax in Tennessee

Most commercial insurance plans sold in Tennessee cover generic alendronate, usually in Tier 1 of the formulary with a $0 to $15 copay. Brand-name Fosamax, by contrast, lands in Tier 3 or Tier 4 on most plans and can carry a copay of $50 to $100 per month even with coverage.

Tennessee's largest commercial insurers by enrollment include BlueCross BlueShield of Tennessee, Cigna, Humana, Aetna, and UnitedHealthcare. All five list generic alendronate in their 2026 formularies, though the exact tier and any prior authorization requirements vary by plan type (HMO, PPO, HDHP) and by employer group contract.

The Affordable Care Act requires plans to cover preventive services rated A or B by the U.S. Preventive Services Task Force (USPSTF) without cost-sharing for eligible patients. The USPSTF recommends screening for osteoporosis in women 65 and older and in younger postmenopausal women at increased risk. [5] However, that recommendation covers bone density screening, not the medication itself. Alendronate treatment is not a USPSTF-listed preventive service, so cost-sharing waivers under the ACA do not automatically apply to the prescription.

If your insurer denies coverage or places alendronate on an unfavorable tier, the appeals process can succeed. A letter of medical necessity from your prescriber citing bone density T-score, fracture history, and the FIT trial data is often sufficient to secure a tier exception.

Compounded Alendronate in Tennessee: Legal Status and Practical Access

Compounded alendronate is legally available in Tennessee through state-licensed 503A compounding pharmacies, and in some clinical arrangements it can be provided at no direct cost to the patient. This is a meaningful option for patients who cannot afford the retail generic or who need a formulation the commercial market does not offer (for example, a liquid suspension for patients who cannot swallow tablets).

Under federal law, Section 503A of the Food, Drug, and Cosmetic Act allows licensed compounding pharmacies to prepare drug preparations for identified individual patients based on a valid prescription. [6] Alendronate is not on the FDA's 503A Bulks Prohibited List, meaning Tennessee-licensed compounding pharmacies can legally compound it. A 503B outsourcing facility (which operates under stricter FDA oversight and can produce larger volumes) may also compound alendronate if it appears on the 503B bulk substances list, but individual patient access through 503B facilities is less common in Tennessee.

The Tennessee State Board of Pharmacy oversees 503A compounding pharmacies operating within the state. A compounding prescription from a Tennessee-licensed prescriber, transmitted to a licensed in-state or out-of-state (NABP-accredited) compounding pharmacy that ships to Tennessee, is legally compliant as of 2026.

One practical point: compounded preparations are not FDA-approved, meaning the finished product has not undergone the same quality, safety, and efficacy review as the commercially manufactured tablet. Patients and prescribers should use compounding pharmacies that are accredited by the Pharmacy Compounding Accreditation Board (PCAB) to reduce quality risk.

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines on the management of postmenopausal osteoporosis state: "Bisphosphonates remain the first-line pharmacologic therapy for most patients with osteoporosis due to their proven anti-fracture efficacy, safety record, and low cost." [7] That cost advantage is amplified when compounding brings the patient's out-of-pocket expense to near zero.

The Cheapest Ways to Get Alendronate in Tennessee Right Now

For most Tennessee patients, five concrete pathways exist to reduce alendronate costs to the lowest possible level.

1. GoodRx or RxSaver coupon at a discount pharmacy. Walmart and Costco consistently price generic alendronate at $9 to $12 per 28-day supply in Tennessee without any coupon. Adding a GoodRx coupon at these pharmacies rarely drops the price further because their cash price is already near the floor. At other chains, GoodRx routinely saves 70% to 80% off the shelf price. [2]

2. Mark Cuban's Cost Plus Drugs. Cost Plus Drugs (costplusdrugs.com) lists alendronate 70 mg at approximately $6 for a 30-day supply as of early 2026, plus a small dispensing and shipping fee. Tennessee residents can use Cost Plus with a valid prescription, and the pharmacy ships to all Tennessee zip codes. This is currently the lowest verifiable cash price for most patients.

3. NeedyMeds patient assistance. NeedyMeds.org maintains a database of manufacturer patient assistance programs (PAPs). Amneal, Teva, and Sun Pharmaceutical, which produce most of the generic alendronate in U.S. distribution, each operate PAPs with income-based eligibility. Qualifying patients may receive alendronate at no cost for 12-month renewable periods. [8]

4. Medicare Part D Low Income Subsidy (Extra Help). Tennessee residents who qualify for the Medicare Part D Extra Help program pay $0 to $4.50 per prescription for Tier 1 generic drugs. Alendronate qualifies in most Part D plans. The Social Security Administration estimates that 13 million Medicare beneficiaries are eligible for Extra Help but only 10 million are enrolled, meaning approximately 3 million nationwide, and an estimated 80,000 to 100 to 000 in Tennessee, are leaving money on the table. [9]

5. 503A compounding pharmacy through a telehealth platform. Several telehealth platforms operating in Tennessee work with PCAB-accredited compounding pharmacies and offer alendronate preparations bundled into a monthly membership fee. In some cases, the compounded medication itself carries no separate drug charge. Patients pay only the telehealth or membership fee, which can bring effective monthly costs to $0 on the medication.

Telehealth Prescribing of Alendronate in Tennessee

Alendronate is fully prescribable via telehealth in Tennessee. The state followed the federal DEA framework for audio-video telehealth and does not require an in-person visit before prescribing non-controlled substances. Alendronate is not a controlled substance, so no DEA waiver or in-person examination is required to receive a first-time prescription via telehealth. [10]

Tennessee's telehealth parity law, enacted in 2016 and updated in 2021, requires commercial insurers to cover telehealth services at the same rate as in-person services when clinically appropriate. A telehealth visit with a Tennessee-licensed physician, nurse practitioner, or physician assistant is legally sufficient to generate a valid alendronate prescription.

What a telehealth prescriber will typically review before prescribing alendronate includes: a recent DEXA scan result (T-score and Z-score), serum calcium and vitamin D 25-OH levels, renal function (eGFR, because alendronate is contraindicated when eGFR <35 mL/min/1.73 m2), and a medication history to screen for drug interactions. [11] Patients who have not had a DEXA scan can often order one through a lab referral at the same telehealth visit.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) recommends initiating pharmacologic therapy in postmenopausal women and men age 50 and older who have a hip or vertebral fracture, a DEXA T-score at the hip or lumbar spine of -2.5 or lower, or low bone mass (T-score between -1.0 and -2.5) with a 10-year FRAX probability of major osteoporotic fracture of at least 20% or hip fracture probability of at least 3%. [12]

How Alendronate Works and Why the Dose Matters

Alendronate binds to hydroxyapatite in bone with high affinity and inhibits farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway used by osteoclasts. The result is impaired osteoclast function, reduced bone resorption, and a net preservation or increase in bone mineral density over time.

Dose matters. The approved doses are:

• 10 mg once daily (postmenopausal osteoporosis, treatment)
• 70 mg once weekly (postmenopausal osteoporosis, treatment; this is the dominant formulation)
• 35 mg once weekly (postmenopausal osteoporosis, prevention)
• 5 mg once daily or 35 mg once weekly (glucocorticoid-induced osteoporosis)
• 40 mg once daily for 6 months (Paget's disease of bone)

The 70 mg once-weekly tablet is the most commonly prescribed and the formulation covered by virtually all Tennessee insurance formularies and patient assistance programs. Once-weekly dosing was shown in a randomized trial published in Bone (N=1,258) to produce equivalent bone mineral density gains at 12 months compared to 10 mg daily, with a comparable adverse event profile. [13]

Administration technique reduces gastrointestinal side effects substantially. The patient should take the tablet first thing in the morning with a full glass of plain water (at least 180 mL / 6 oz), remain upright for at least 30 minutes afterward, and avoid food, other beverages, and medications during that window. Esophageal irritation, the most common adverse effect leading to discontinuation, drops when these instructions are followed correctly.

Monitoring and Duration of Therapy in Tennessee Clinical Practice

The American College of Obstetricians and Gynecologists (ACOG) and the Endocrine Society both support reassessing therapy after five years of oral bisphosphonate use. [14] At that point, a repeat DEXA and fracture risk assessment guides one of three decisions: continue therapy, transition to a drug holiday (typically 1 to 2 years), or switch to a different agent.

For patients at high fracture risk (T-score <-2.5 at the hip, prior fracture, or FRAX 10-year major osteoporotic fracture risk above 20%), most guidelines recommend continuing alendronate beyond five years rather than stopping. The FLEX trial (N=1,099) followed women who had taken alendronate for five years and then randomized them to continue for five more years or switch to placebo. Those continuing alendronate had a 55% lower rate of clinical vertebral fractures over the subsequent five years, though the reduction in hip fracture did not reach statistical significance in that subgroup analysis. [15]

Renal monitoring is required before and during therapy. Alendronate is contraindicated in patients with creatinine clearance <35 mL/min. Tennessee prescribers using telehealth platforms should obtain a basic metabolic panel within 6 months of the prescribing visit if no recent labs are available.

Drug Interactions and Contraindications Tennessee Patients Should Know

Several medications and supplements reduce alendronate absorption and should not be taken within 30 minutes (ideally 2 hours) of the weekly dose:

• Calcium supplements
• Antacids containing aluminum, magnesium, or calcium
• Iron supplements
• Multivitamins containing mineral cations

NSAIDs taken concurrently with alendronate may increase the risk of upper gastrointestinal adverse events, though the absolute risk increase is small at typical doses.

Osteonecrosis of the jaw (ONJ) is a rare but serious complication associated with bisphosphonate use, occurring primarily in patients receiving intravenous bisphosphonates for oncology indications rather than oral alendronate at osteoporosis doses. The American Dental Association states that the risk of ONJ with oral bisphosphonates at osteoporosis doses is estimated at 1 in 10,000 to 1 in 100,000 patient-years of exposure. [16] Tennessee patients planning invasive dental procedures should inform their dentist about alendronate use, and a brief drug holiday (2 to 3 months before and after the procedure) may be appropriate for high-risk procedures, though evidence supporting this practice is limited.

Atypical femoral fractures are a second rare adverse event associated with long-duration bisphosphonate use. The risk increases with duration of therapy and drops sharply after discontinuation. The FDA label for alendronate notes that atypical femoral fractures have been reported at a background rate of approximately 2 to 3 per 10,000 patient-years at 5 years of use, rising to roughly 78 per 10,000 patient-years at 8 or more years. [1]

Alendronate vs. Other Osteoporosis Medications: Context for Tennessee Patients

For patients who cannot tolerate oral alendronate or who have renal impairment, alternative medications include:

• Risedronate (Actonel): Another oral bisphosphonate; similar efficacy and safety profile, available as 35 mg once weekly. Generic risedronate typically runs $20 to $30 per month at Tennessee pharmacies.
• Zoledronic acid (Reclast): IV bisphosphonate given once yearly; requires an infusion center visit but eliminates the weekly pill burden. Covered by most Tennessee commercial plans and Medicare Part B.
• Denosumab (Prolia): Subcutaneous injection every 6 months; a different mechanism (RANK-L inhibitor). Higher cost ($1,000 to $1,500 per injection cash pay), but assistance programs are available.
• Raloxifene (Evista): Selective estrogen receptor modulator; reduces vertebral but not hip fracture risk. Generic raloxifene is available in Tennessee for approximately $30 to $50 per month cash.

For most newly diagnosed Tennessee patients without contraindications, generic alendronate 70 mg once weekly remains the lowest-cost, highest-evidence first-line choice. The BHOF position statement and AACE guidelines both rank it there. [7,12]